p-(1-Methylcyclopropyl)acetophenone | 42427-46-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: p-(1-Methylcyclopropyl)acetophenone
• 英文别名: 1-(p-Acetylphenyl)-1-methylcyclopropan；1-Methyl-1-(p-acetylphenyl)cyclopropan；1-[4-(1-Methylcyclopropyl)phenyl]ethanone
• CAS: 42427-46-3
• 化学式: C₁₂H₁₄O
• 分子量: 174.243
• InChiKey: PCXMWIMJQUHXKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  p-(1-Methylcyclopropyl)acetophenone 在 氢溴酸 作用下， 生成 trans-2-(p-Acetylphenyl)but-2-en
  参考文献：
  名称：

  Shabarov,Yu.S. et al., Journal of Organic Chemistry USSR (English Translation), 1973, vol. 9, p. 1215 - 1218

  摘要：

  DOI：
• 作为产物：
  描述：

  (1-methylcyclopropyl)benzene 、 乙酰氯 在 三氯化铝 作用下， 以 氯仿 为溶剂， 以60%的产率得到p-(1-Methylcyclopropyl)acetophenone
  参考文献：
  名称：

  p-(2-取代环丙基)-α-甲基苄基氯化物溶剂分解中的取代基效应

  摘要：

  在 80% 丙酮水溶液中测量了对（顺式或反式-2-取代的环丙基）-α-甲基苄基氯的溶剂分解速率，包括相对于氢取代基的给电子和吸电子取代基。反式异构体比相应的顺式衍生物更具反应性，其中环丙基和苯基无法获得最有利的“二等分”构象，环丙基将电子释放到苯环。反式异构体在 45°C 下的相对速率通过 σm 值与 ρ 值为 -3.14 和相关系数为 0.97 的相关性最好，表明环丙烷环是一种较差的共振效应发射器。通过LSFE方程分析取代基效应。

  DOI：

  10.1246/bcsj.64.2954

文献信息

• Direct synthesis of ethers from aldehydes and ketones. One-pot reductive etherification of benzaldehydes, alkyl aryl ketones, and benzophenones
  作者：S. S. Mochalov、A. N. Fedotov、E. V. Trofimova、N. S. Zefirov

  DOI：10.1134/s1070428016040047

  日期：2016.4

  Benzyl alcohols formed by the reduction of benzaldehydes, alkyl aryl ketones, and benzophenones with sodium tetrahydridoborate in alcohols undergo in situ etherification with the solvent in the presence of a catalytic amount of HCl. Thus the process may be regarded as one-pot transformation of carbonyl compounds into the corresponding benzyl ethers. The yields of ethers depend on the substituent nature

  通过在醇中催化量的四氢硼酸钠将苯甲醛，烷基芳基酮和二苯甲酮还原而形成的苄醇在催化量的HCl的存在下与溶剂进行原位醚化。因此，该方法可以被认为是羰基化合物一锅转化为相应的苄基醚。醚的产率取决于初始羰基化合物的芳族片段中的取代基性质以及用作还原介质的醇。
• 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10160762B2

  公开（公告）日：2018-12-25

  The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.

  本发明涉及式（I）的6-烷基二氢吡唑嘧啶酮化合物，该化合物可作为治疗剂用于治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病。本发明还涉及使用此类化合物治疗神经和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能低下或基底节功能障碍相关的疾病。
• Hydrochloric acid as an efficient catalyst for intermolecular condensation of alcohols. A simple and highly efficient synthesis of unsymmetrical ethers from benzylic alcohols and alkanols
  作者：S. S. Mochalov、A. N. Fedotov、E. V. Trofimova、N. S. Zefirov

  DOI：10.1134/s107042801509002x

  日期：2015.9

  Benzylic alcohols and diarylmethanols with electron-donating substituents in the aromatic ring reacted with aliphatic alcohols in the presence of a catalytic amount of HCl to give the corresponding alkyl arylmethyl ethers. The reactivity of diarylmethanols in the intermolecular dehydration depended on the nature of substituents in the aromatic rings and structure of aliphatic alcohol.
• 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3302484B1

  公开（公告）日：2020-09-16
• [EN] 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE UTILISÉS COMME INHIBITEURS DE PDE2
  申请人：MERCK SHARP & DOHME

  公开号：WO2016196071A1

  公开（公告）日：2016-12-08

  The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.